The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

alethiabio.com

Founded Year

2002

Stage

Unattributed | Alive

Total Raised

$17.8M

Last Raised

$1.6M | 4 yrs ago

About Alethia BioTherapeutics

Alethia BioTherapeutics is a biotechnology company that develops monoclonal antibody therapeutics to clinically relevant targets identified using its STAR discovery technology.

Alethia BioTherapeutics Headquarter Location

141, President-Kennedy Ave. Suite SB-5100

Montreal, Quebec, H2X 1Y4,

Canada

514-858-7666

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Alethia BioTherapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Alethia BioTherapeutics is included in 2 Expert Collections, including Cancer.

C

Cancer

4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

B

Biopharma Tech

838 items

Alethia BioTherapeutics Patents

Alethia BioTherapeutics has filed 25 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

4/25/2016

11/28/2017

Immunology, Clusters of differentiation, Units of information, Immune system, Monoclonal antibodies for tumors

Grant

Application Date

4/25/2016

Grant Date

11/28/2017

Title

Related Topics

Immunology, Clusters of differentiation, Units of information, Immune system, Monoclonal antibodies for tumors

Status

Grant

Latest Alethia BioTherapeutics News

Alethia Biotherapeutics Announces Receipt of FDA Authorization to Begin Phase 2 Development for its EMT Inhibitor, AB-16B5

May 21, 2020

| Source: Alethia Biotherapeutics multilang-release MONTREAL, May 21, 2020 (GLOBE NEWSWIRE) -- Alethia Biotherapeutics announced today that the U.S. Food and Drug Administration has cleared its Phase 2 Investigational new drug (IND) application for AB-16B5, a potent inhibitor of the epithelial to mesenchymal transition (EMT). This allows the Company to initiate a multi-center trial of AB-16B5 in combination with docetaxel in previously treated subjects with metastatic non-small cell lung cancer (NSCLC) who have experienced disease progression following treatment with a platinum-containing doublet treatment and an anti-PD1 or PD-L1 immune checkpoint antibody. “We are extremely pleased to have achieved this important milestone in the development of AB-16B5 and to continue to advance the clinical development of this promising antibody” commented Yves Cornellier, President and CEO of Alethia. “EMT is a central enabler for solid tumor progression because it triggers metastatic invasion, resistance to several classes of anti-cancer drugs and contributes to immune evasion. There is also increasing evidence that EMT contributes to resistance to immune checkpoint inhibitors. AB-16B5 may play an important role in overcoming these problems”, added Dr. Mario Filion, Chief Scientific Officer. Study overview This multicenter, open-label, Phase 2 study of AB-16B5 in combination with docetaxel (NCT04364620) will enroll approximately 40 subjects with advanced NSCLC who have previously been treated with a platinum-containing doublet treatment and an anti-PD1 or PD-L1 immune checkpoint antibody, a patient population with very limited options. The primary objectives are to assess the anti-tumor efficacy of AB-16B5 in combination with docetaxel as measured by objective response rate and to determine the safety and tolerability of the combined drugs. Secondary objectives of the study include clinical benefit rate, percentage of subjects with complete response or partial response, duration of stable disease, progression-free survival and overall survival. About AB-16B5 AB-16B5 is a humanized IgG2 monoclonal antibody that selectively binds and inhibits tumor-associated secreted clusterin, a protein expressed in many cancers. Tumor-associated secreted clusterin is induced early in the EMT cascade and its inhibition with AB-16B5 stops and reverts EMT in animal models. A Phase 1 study in subjects with advanced carcinomas demonstrated that AB-16B5 was safe and well tolerated and provided clinical benefit to several subjects. Stable disease was observed in several patients for up to one year. There was also evidence of EMT inhibition in tumor biopsies. About Alethia Biotherapeutics Alethia is a privately held clinical stage biotechnology company located in Montreal. Alethia develops immunotherapeutics for the treatment of cancer. Contacts

Alethia BioTherapeutics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Alethia BioTherapeutics Rank

  • When was Alethia BioTherapeutics founded?

    Alethia BioTherapeutics was founded in 2002.

  • Where is Alethia BioTherapeutics's headquarters?

    Alethia BioTherapeutics's headquarters is located at 141, President-Kennedy Ave., Montreal.

  • What is Alethia BioTherapeutics's latest funding round?

    Alethia BioTherapeutics's latest funding round is Unattributed.

  • How much did Alethia BioTherapeutics raise?

    Alethia BioTherapeutics raised a total of $17.8M.

  • Who are the investors of Alethia BioTherapeutics?

    Investors of Alethia BioTherapeutics include Go Capital Fund, BDC Healthcare Venture Fund, AgeChem Venture Fund, AgeChem, Epicentre Technologies Corporation and 3 more.

  • Who are Alethia BioTherapeutics's competitors?

    Competitors of Alethia BioTherapeutics include Amicus Therapeutics, Cellerant Therapeutics, Zyngenia, NewLink Genetics, RAVEN Biotechnologies and 13 more.

You May Also Like

B
Bolder BioTechnology

Bolder BioTechnology, Inc. uses advanced protein engineering technologies to create human protein pharmaceuticals with enhanced therapeutic properties. Most protein pharmaceuticals are rapidly eliminated by the body, which limits their effectiveness and requires that they be administered by frequent, often daily, injection. The company's products are designed to last longer in the body, which aims to allow them to be administered less frequently, e.g., once per week to once per month, and maximizes their therapeutic benefits to patients. Company scientists combine protein structure/function information with targeted protein modification technologies to rationally design long-acting protein pharmaceuticals that, in many cases, are 10-100-fold more potent than competing products prepared using non-targeted protein modification technologies. Bolder BioTechnology has a robust pipeline of products in preclinical development, including products for the treatment of hematological and endocrine disorders, cancer and infectious disease. The company intend to commercialize these products independently and through strategic alliances with corporate partners.

A
Abeome

Abeome is a biotechnology firm dedicated to leveraging its technology that aims to enhance the speed, efficiency and stability of developing and producing monoclonal antibodies.

S
Spaltudaq

Spaltudaq Corporation, a privately-held biotechnology company based in Seattle, is focused on developing therapeutic antibodies for the treatment of inflammation, infectious disease and cancer. Our technology harnesses the power of the human immune system to identify tumor-specific or pathogen-specific monoclonal antibodies from human tissue samples.

Ventria Logo
Ventria

Ventria Biosciences is a biotechnology company engaged in the development of recombinant proteins using its ExpressTec technology, which achieves yields far greater than those of the next-best plant-based system.

Cellerant Therapeutics Logo
Cellerant Therapeutics

Cellerant Therapeutics is a clinical stage biotechnology company focused on the regulation of the hematopoietic (blood-forming) system. The Company is developing human stem cell and antibody therapies for oncology applications and blood-related disorders. Cellerant's lead product, CLT-008 is currently in two Phase 1 clinical trials in patients with hematological malignancies. The Company also has a Cancer Stem Cell (CSC) antibody discovery program focused on therapies for acute myeloid leukemia, multiple myeloma and myelodysplastic syndrome.

I
Itero Biopharmaceuticals

Itero Biopharmaceuticals is a developer of value-added follow-on and proteins and antibodies.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.